Basaglar: A Hypersensitivity Reaction

Departments

Clinical Diabetes 2018 Apr; 36(2): 205-207. https://doi.org/10.2337/cd17-0051

Article Figures & Tables

TABLE 1.

Proportion of Patients With Detected Antibodies in the ELEMENT 2 Trial

Population	Visit	Basaglar Patients With Detected Antibodies (n [%])	Lantus Patients With Detected Antibodies (n [%])
Full analysis set	Baseline	20 (5.5)	13 (3.6)
	Week 24 overall	56 (15.3)	40 (11.0)
	Week 24 LOCF	30 (8.2)	22(6.0)
Previous Lantus patients	Baseline	10 (6.6)	6 (4.4)
	Week 24 overall	29 (19.2)	11 (7.9)
	Week 24 LOCF	13 (8.6)	5 (3.6)
Previously insulin-naive patients	Baseline	10 (4.7)	7 (3.1)
	Week 24 overall	27 (12.6)	29 (12.8)
	Week 24 LOCF	17 (7.9)	17 (7.5)